



XDNA

Kelly CRISPR & Gene Editing Technology ETF



Why Invest in XDNA ETF

XDNA is designed to capitalize on the next generation of healthcare by investing in companies disrupting the genomic and life science industries.

- **Exposure to Innovation:** Aims for thematic multi-cap exposure to innovative companies focusing on CRISPR and gene editing technology companies.
- **High Growth Potential:** Aims to capture long-term growth with low correlation of relative returns to traditional growth and healthcare strategies. Enables investors to access growth potential through companies that we believe are positioned to benefit from disrupting the genomic and life science industries.
- **Tool for Diversification:** Offers a tool for diversification due to little overlap with traditional indices. It can be a complement to traditional healthcare and growth strategies.
- **Targeted Exposure:** XDNA is a concentrated portfolio that provides access to emerging areas within the Health Care Sector at the intersection of science and technology.
- **Cost Effective:** In a single trade, XDNA delivers access to dozens of companies with exposure to the emerging CRISPR and gene editing theme seeking to provide a lower cost alternative to mutual funds, private equity funds, and venture capital management in an Exchange Traded Fund (ETF).

Fund Overview

- CRISPR & Gene Editing Technology ETF seeks to provide total return by investing in a passively managed, concentrated portfolio of companies that engage in CRISPR & gene editing technology activities.
- Targets companies in the US and developed markets that operate across three CRISPR & Gene Editing sub-sectors, including:
 - CRISPR & Gene Editing Technology sub-sector: Includes companies that specialize in DNA modification systems, and technologies, for a variety of applications including basic biological research, development of biotechnological products, and for the treatment of diseases. CRISPR & gene editing technology enables genetic elements to be mutated, silenced, induced or replaced. The most common use of DNA modification technology is the targeting of cells within the body to treat genetic disease.
 - Gene Editing Development Solutions sub-sector: Includes companies that have deep scientific, technical and clinical development experience, potentially along with an intellectual property portfolio, that have rights to develop CRISPR or gene-editing based therapeutic products or targets and/or jointly develop potential products with CRISPR & gene editing technology companies to create a new class of therapeutic products.
 - Gene Editing Sequencing Solutions sub-sector: Includes companies that specialize in next-generation sequencing that may be used at various stages of a genome editing workflow. The companies provide sequencing methods to determine the impact of an edited sequence on the structured function of genes and analysis tools for CRISPR and gene splicing and editing.
- Companies are initially identified by industry and sector and are then further reviewed on the basis of operations related to CRISPR & Gene Editing technology activities.

Top 10 Holdings

As of March 31, 2022

| Security Name | Weight |
|----------------------------------|--------|
| EDITAS MEDICINE INC | 11.89% |
| CRISPR THERAPEUTICS AG | 10.95% |
| INTELLIA THERAPEUTICS INC | 7.88% |
| BEAM THERAPEUTICS INC | 7.84% |
| ALLOGENE THERAPEUTICS INC | 5.33% |
| ABBVIE INC | 5.32% |
| SANGAMO THERAPEUTICS INC | 5.32% |
| ILLUMINA INC | 5.17% |
| THERMO FISHER SCIENTIFIC INC COM | 5.13% |
| CARIBOU BIOSCIENCES INC | 4.93% |

Holdings are subject to change.

Description

XDNA seeks to track the total return performance, before fees and expenses, of the Strategic CRISPR & Gene Editing Technology Index, which measures the performance of companies that specialize in CRISPR & DNA modification systems, and technologies, for variety of applications including basic biological research, development of biotechnological products, and treatment of diseases as well as next-generation sequencing that may be used at various stages of a genome editing workflow.


Fund Details

| | |
|--------------------|--------------------|
| Fund Inception | 1/12/2022 |
| Ticker | XDNA |
| Net Assets | \$1,242,817.73 |
| Shares Outstanding | 100000 |
| Primary Exchange | Nasdaq |
| CUSIP | 48817R 706 |
| ISIN | US48817R7061 |
| Fund Type | Indexed Equity ETF |
| Expense Ratio | 0.78% |
| Number of Holdings | 24 |
| Dividend Frequency | Annually |

Data as of 03/31/2022

Sector Breakdown

As of As of March 18, 2022



- CRISPR & Gene Editing Technology
- Gene Editing Development Solutions
- Gene Editing Sequencing Solutions

Performance

As of March 31, 2022

| | 1 Month | Since Inception (1/12/2022) |
|---------------|----------------|--|
| Fund NAV | -6.98% | -15.45% |
| Closing Price | -7.00% | -15.03% |

Investors should carefully consider the investment objectives, risks, and charges and expenses of the fund before investing. The prospectus contains this and other information about the fund, and it should be read carefully before investing. Investors may obtain a copy of the prospectus by visiting KellyETFs.com.

The fund is distributed by Foreside Fund Services, LLC.

Limited Operating History Risk. The Fund is a recently organized investment company with a limited operating history. As a result, prospective investors have a limited track record or history on which to base their investment decision.

DNA Modification Technology Company Risk. DNA modification technology companies face intense competition, and products and services with a potentially short product life. These companies will generally require large amounts of capital expenditures on research and development, with no guarantee that the product or service would be successful. They may be heavily dependent on intellectual property rights. The laws related to these rights can vary and there is no guarantee that a company will be able to successfully protect their intellectual property rights. These companies, like other health care companies, are subject to various government and regulator oversight that could hamper or impede their operations.

Concentration Risk. The Fund's investments will be concentrated in an industry or group of industries to the extent that the Index is so concentrated. In such event, the value of the Shares may rise and fall more than the value of shares of a fund that invests in securities of companies in a broader range of industries.

Foreign Securities Risk. Investments in non-U.S. securities involve certain risks that may not be present with investments in U.S. securities. For example, investments in non-U.S. securities may be subject to risk of loss due to foreign currency fluctuations or to political or economic instability.

Date of first use: 01/18/2022